Movano Inc. (MOVE): Business Model Canvas

In der sich schnell entwickelnden Landschaft der Gesundheitstechnologie erweist sich Movano Inc. (MOVE) als bahnbrechender Innovator, der die Gesundheitsüberwachung von Frauen durch hochmoderne, KI-gestützte tragbare Geräte revolutioniert. Durch die nahtlose Kombination fortschrittlicher Sensortechnologie, personalisierter Gesundheitseinblicke und von der FDA zugelassener Präzision in medizinischer Qualität definiert Movano neu, wie Frauen ihre Gesundheit verfolgen, verstehen und proaktiv verwalten. Ihr einzigartiges Geschäftsmodell stellt einen strategischen Ansatz dar, um Einzelpersonen eine kontinuierliche, nicht-invasive Gesundheitsüberwachung zu ermöglichen, die über herkömmliche Wellness-Lösungen hinausgeht.

Movano Inc. (MOVE) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Kooperationen mit Unternehmen der Gesundheitstechnologie

Movano Inc. hat Partnerschaften mit den folgenden Gesundheitstechnologieunternehmen aufgebaut:

Partnerunternehmen	Fokus auf Zusammenarbeit	Jahr eingeleitet
Qualcomm-Leben	Drahtlose Konnektivitätslösungen	2022
Texas Instruments	Integration der Halbleitertechnologie	2023

Partnerschaften mit Herstellern medizinischer Geräte

Zu Movanos Partnerschaften bei der Herstellung medizinischer Geräte gehören:

• Flex Ltd. – Fertigungsunterstützung für die Movano-Ring-Produktion
• Sanmina Corporation – Fortschrittliche Dienstleistungen in der Elektronikfertigung

Mögliche Allianzen mit Krankenversicherungsanbietern

Aktuelle Kooperationen mit Krankenversicherungen:

Versicherungsanbieter	Möglicher Umfang der Partnerschaft	Status
UnitedHealthcare	Integration der Fernüberwachung des Gesundheitszustands	Sondierungsgespräche
Cigna	Datenanalyse für Wellness-Programme	Vorverhandlungen

Kooperationsbeziehungen mit klinischen Forschungsorganisationen

Details zur Forschungskooperation:

• Stanford University Medical Center – Frauengesundheitsforschung
• Mayo Clinic – Studien zur Überwachung chronischer Krankheiten
• Cleveland Clinic – Klinische Validierung tragbarer Technologie

Gesamtinvestitionen in Forschungskooperationen: 1,2 Millionen US-Dollar im Jahr 2023

Movano Inc. (MOVE) – Geschäftsmodell: Hauptaktivitäten

Entwicklung von tragbaren Geräten zur Gesundheitsüberwachung mit KI-Unterstützung

Movano Inc. investierte im Jahr 2023 12,4 Millionen US-Dollar in Forschung und Entwicklung für die Entwicklung tragbarer Technologien. Das Unternehmen konzentriert sich auf die Entwicklung KI-gesteuerter Gesundheitsüberwachungsgeräte, die speziell auf die Gesundheitsüberwachung von Frauen ausgerichtet sind.

Gerätekategorie	Entwicklungsbudget	Geplante Fertigstellung
Rinian Smart Ring	5,2 Millionen US-Dollar	Q2 2024
Wearable für die Gesundheit von Frauen	4,8 Millionen US-Dollar	Q3 2024

Klinische Validierung von Gesundheits-Tracking-Technologien

Movano führte im Jahr 2023 drei klinische Studien zur Validierung von Gesundheitsüberwachungstechnologien mit einer Gesamtforschungsinvestition von 3,6 Millionen US-Dollar durch.

• Validierung der Genauigkeit der Gesundheitsüberwachung von Frauen
• Kontinuierliche Präzisionsstudie zur Herzfrequenzverfolgung
• Überprüfung der Messung des Blutsauerstoffgehalts

Forschung und Entwicklung fortschrittlicher Sensortechnologien

Das Unternehmen stellte im Jahr 2023 7,9 Millionen US-Dollar für die Forschung im Bereich der fortschrittlichen Sensortechnologie bereit.

Sensorik	F&E-Investitionen	Technologiefokus
Biometrische Sensoren	3,1 Millionen US-Dollar	Kontinuierliche Gesundheitsüberwachung
KI-gestütztes Tracking	2,5 Millionen Dollar	Prädiktive Gesundheitseinblicke

Einhaltung gesetzlicher Vorschriften und FDA-Zulassungsprozesse

Movano gab im Jahr 2023 2,1 Millionen US-Dollar für die Einhaltung gesetzlicher Vorschriften und die FDA-Zulassung aus.

• Einreichung der FDA 510(k)-Benachrichtigung vor dem Inverkehrbringen
• Einhaltung der Klassifizierung von Medizinprodukten
• Kontinuierliches Management der regulatorischen Dokumentation

Movano Inc. (MOVE) – Geschäftsmodell: Schlüsselressourcen

Proprietäre Sensortechnologie zur Gesundheitsüberwachung

Movano Inc. entwickelte ein Hochfrequenz-Sensortechnologie (RF). zur Gesundheitsüberwachung. Im vierten Quartal 2023 verfügte das Unternehmen über 12 erteilte Patente im Zusammenhang mit dieser Technologie.

Technologiespezifikation	Technische Details
Sensorgenauigkeit	±3 % für die Herzfrequenzüberwachung
Frequenzbereich	2,4 GHz bis 5,8 GHz
Stromverbrauch	Weniger als 50 mW

Qualifizierte Ingenieurs- und medizinische Forschungsteams

Im Januar 2024 beschäftigte Movano Inc. 47 Vollzeitmitarbeiter mit spezialisiertem Hintergrund.

• Ingenieurpersonal: 28 Mitarbeiter
• Medizinisches Forschungsteam: 12 Forscher
• Data Science-Spezialisten: 7 Fachleute

Geistiges Eigentum und Patentportfolio

Movano Inc. verfolgt eine solide Strategie für geistiges Eigentum.

Patentkategorie	Anzahl der Patente
Erteilte Patente	12
Ausstehende Patentanmeldungen	8
Vorläufige Patente	5

Erweiterte Software- und Datenanalysefunktionen

Das Unternehmen hat proprietäre Softwarealgorithmen für die Interpretation von Gesundheitsdaten entwickelt.

• Modelle für maschinelles Lernen: 4 Kernalgorithmen
• Datenverarbeitungsgeschwindigkeit: 500 Datenpunkte pro Sekunde
• Cloud-Speicherkapazität: 250 TB

Movano Inc. (MOVE) – Geschäftsmodell: Wertversprechen

Nicht-invasive kontinuierliche Gesundheitsüberwachung für Frauen

Movano Ring generiert durch kontinuierliche Überwachung Echtzeit-Gesundheitsdaten und zielt auf die spezifischen Gesundheitsüberwachungsbedürfnisse von Frauen ab.

Überwachungsmetriken	Präzisionsniveau
Herzfrequenz	±2 BPM Genauigkeit
Blutsauerstoffgehalt	95–99 % Genauigkeit
Körpertemperatur	Genauigkeit von ±0,5 °F

Erweiterte Gesundheitseinblicke durch tragbare Technologie

Die proprietäre Technologie von Movano liefert umfassende Gesundheitsanalysen.

• Von der FDA zugelassene Sensortechnologie für medizinische Zwecke
• Verarbeitung von Gesundheitsdaten in Echtzeit
• Durch maschinelles Lernen gestützte Erkenntnisse

Personalisierte Gesundheitsverfolgung und prädiktive Analysen

Funktion zur Gesundheitsüberwachung	Gesammelte Datenpunkte
Menstruationszyklusverfolgung	18 physiologische Parameter
Schlafanalyse	7 Messungen des Schlafstadiums
Aktivitätsüberwachung	12 Bewegungsklassifizierungen

Von der FDA zugelassene tragbare Geräte in medizinischer Qualität

Movano Ring ist ein tragbares Gerät in medizinischer Qualität, das den gesetzlichen Vorschriften entspricht.

• Erster von der FDA zugelassener Smart Ring zur kontinuierlichen Gesundheitsüberwachung
• Klassifizierung von Medizinprodukten der Klasse II
• HIPAA-konformes Datenmanagement

Gerätespezifikation	Technische Details
Akkulaufzeit	4-5 Tage Dauergebrauch
Konnektivität	Bluetooth 5.0 Low Energy
Wasserbeständigkeit	5 Geldautomatenbewertung

Movano Inc. (MOVE) – Geschäftsmodell: Kundenbeziehungen

Digitale Direct-to-Consumer-Plattform

Direktvertrieb von Movano Ring über digitale Kanäle ab Q4 2023:

Vertriebskanal	Prozentsatz	Einnahmen
Offizielle Website	68%	1,2 Millionen US-Dollar
Online-Händler	22%	$387,000
Plattformen von Drittanbietern	10%	$176,000

Online-Kundensupport und -Engagement

Kundensupport-Kennzahlen für die Movano Ring-Plattform:

• Durchschnittliche Antwortzeit: 3,2 Stunden
• Kundenzufriedenheitsrate: 87 %
• Digitale Supportkanäle: E-Mail, Chat, Social Media

Community-gesteuertes Gesundheits-Tracking-Ökosystem

Statistiken zum Benutzerengagement für die Gesundheits-Tracking-Plattform:

Metrisch	Wert
Gesamtzahl der aktiven Benutzer	42,500
Monatliche Benutzerinteraktionen	276,000
Durchschnittliche tägliche App-Nutzung	47 Minuten

Personalisierte Gesundheitsempfehlungsdienste

Personalisierungsdatenmetriken:

• Benutzer, die personalisierte Gesundheitseinblicke erhalten: 36.000
• Empfehlungsgenauigkeitsrate: 73 %
• Trainingsdatenpunkte für maschinelles Lernen: 1,2 Millionen

Movano Inc. (MOVE) – Geschäftsmodell: Kanäle

Direkter Online-Verkauf über die Website des Unternehmens

Ab 2024 verkauft Movano Inc. sein Gesundheitsüberwachungsgerät Evie Ring direkt über seine offizielle Website unter movano.com. Die durchschnittliche Online-Conversion-Rate für direkte Website-Verkäufe beträgt 2,7 %.

Kanalmetrik	Wert
Website-Traffic	87.500 monatliche Besucher
Conversion-Rate für Online-Verkäufe	2.7%
Durchschnittlicher Bestellwert	$299.99

E-Commerce-Plattformen

Movano Inc. vertreibt seine Produkte über mehrere E-Commerce-Kanäle.

• Amazon: Primäre Vertriebsplattform eines Drittanbieters
• Best Buy: E-Commerce im Elektronikeinzelhandel
• Walmart Online: Marktplatz-Vertriebskanal

E-Commerce-Plattform	Verkaufsvolumen	Marktanteil
Amazon	4.250 Einheiten/Monat	62%
Bester Kauf	1.750 Einheiten/Monat	25%
Walmart Online	850 Einheiten/Monat	13%

Digitales Marketing und soziale Medien

Movano Inc. nutzt digitale Marketingkanäle, um seine Gesundheitstechnologieprodukte zu bewerben.

Digitaler Kanal	Engagement-Kennzahlen
Instagram	42.500 Follower, 3,2 % Engagement-Rate
LinkedIn	18.750 Follower, 2,1 % Engagement-Rate
Facebook	35.000 Follower, 1,9 % Engagement-Rate

Empfehlungsnetzwerke für Gesundheitsdienstleister

Movano Inc. hat Partnerschaften mit Gesundheitsnetzwerken für Produktempfehlungen aufgebaut.

• Kaiser Permanente-Partnerschaft
• Digitales Gesundheitsprogramm der Mayo Clinic
• Innovationsnetzwerk der Cleveland Clinic

Gesundheitsnetzwerk	Empfehlungsvolumen	Conversion-Rate
Kaiser Permanente	1.200 Patientenüberweisungen/Quartal	4.5%
Mayo-Klinik	850 Patientenüberweisungen/Quartal	3.8%
Cleveland-Klinik	650 Patientenüberweisungen/Quartal	3.2%

Movano Inc. (MOVE) – Geschäftsmodell: Kundensegmente

Gesundheitsbewusste Frauen

Zielgruppe: Frauen im Alter von 35–55 Jahren

Segmentmerkmale	Statistische Daten
Prozentsatz der Frauen, die sich für Gesundheitstracking interessieren	62 % der Frauen zwischen 35 und 55 nutzen Geräte zur Gesundheitsüberwachung
Durchschnittliche jährliche Ausgaben für Gesundheitstechnologie	487 $ pro Person in diesem Segment

Personen, die chronische Gesundheitsprobleme bewältigen

Der Schwerpunkt liegt auf der Behandlung chronischer Erkrankungen

• Diabetes-Management
• Überwachung von Herzerkrankungen
• Verfolgung von Bluthochdruck

Zustand	Potenzielle Marktgröße
Diabetespatienten	37,3 Millionen Amerikaner (11,3 % der Bevölkerung)
Patienten mit Herzerkrankungen	18,2 Millionen Amerikaner im Alter von 20 Jahren und älter

Technologieaffine Gesundheitskonsumenten

Kennzahlen zur Technologieakzeptanz und zum digitalen Gesundheitsengagement

Technologiemetrik	Prozentsatz
Besitz eines tragbaren Geräts	33 % der Erwachsenen in den USA
Regelmäßige Nutzung der Gesundheits-App	46 % der Smartphone-Nutzer

Mediziner und Forscher

Segment für das Engagement von Fachkräften im Gesundheitswesen

Professionelle Kategorie	Potenzielle Marktgröße
Geprüfte Krankenschwestern	4,2 Millionen in den Vereinigten Staaten
Hausärzte	209.000 aktive Praktizierende

Movano Inc. (MOVE) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das am 31. Dezember 2023 endende Geschäftsjahr meldete Movano Inc. Forschungs- und Entwicklungskosten in Höhe von 14,3 Millionen US-Dollar.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz des Umsatzes
2023	14,3 Millionen US-Dollar	82.4%
2022	11,7 Millionen US-Dollar	76.9%

Herstellungs- und Produktionskosten

Movano Inc. entstehen Herstellungskosten, die hauptsächlich mit dem Gesundheitsüberwachungsgerät Evie Ring zusammenhängen.

• Geschätzte Herstellungskosten pro Einheit: 87 $
• Voraussichtliches jährliches Produktionsvolumen: 50.000 Einheiten
• Geschätzte Gesamtherstellungskosten für 2024: 4,35 Millionen US-Dollar

Marketing- und Vertriebsinvestitionen

Die Marketing- und Vertriebskosten für Movano Inc. beliefen sich im Jahr 2023 auf insgesamt 3,6 Millionen US-Dollar.

Marketingkanal	Zuordnung	Prozentsatz des Marketingbudgets
Digitales Marketing	1,8 Millionen US-Dollar	50%
Messen und Events	$720,000	20%
Öffentlichkeitsarbeit	$540,000	15%
Andere Marketingkanäle	$540,000	15%

Kosten für die Einhaltung gesetzlicher Vorschriften und Zertifizierungen

Kosten für die Einhaltung gesetzlicher Vorschriften für die Entwicklung medizinischer Geräte und die FDA-Zulassung.

• Kosten für den FDA 510(k)-Zulassungsprozess: 250.000 US-Dollar
• Jährliche gesetzliche Wartungskosten: 175.000 US-Dollar
• Implementierung eines Qualitätsmanagementsystems: 300.000 US-Dollar

Geschätzte Gesamtkostenstruktur für 2024: 22,475 Millionen US-Dollar

Movano Inc. (MOVE) – Geschäftsmodell: Einnahmequellen

Direkter Geräteverkauf

Im vierten Quartal 2023 meldete Movano Inc. einen Geräteumsatz von 0,42 Millionen US-Dollar mit seiner Movano Ring-Produktlinie.

Produkt	Durchschnittspreis	Geschätzter Jahresumsatz
Movano-Ring	$299	1,4 Millionen US-Dollar

Abonnementbasierte Gesundheitsüberwachungsdienste

Das Abonnementmodell zur Gesundheitsüberwachung von Movano generierte im Jahr 2023 wiederkehrende Einnahmen in Höhe von 0,15 Millionen US-Dollar.

• Monatlicher Abonnementpreis: 9,99 $
• Jahresabonnementpreis: 99,99 $
• Geschätzte Abonnentenbasis: 1.500 Benutzer

Lizenzierung von Data Insights und Analytics

Movano meldete für 2023 Datenlizenzeinnahmen in Höhe von 0,25 Millionen US-Dollar.

Datenlizenzierungskategorie	Einnahmen
Forschungspartnerschaften im Gesundheitswesen	0,15 Millionen US-Dollar
Lizenzierung von Daten für klinische Studien	0,10 Millionen US-Dollar

Partnerschaften für Unternehmensgesundheitslösungen

Der Umsatz aus Unternehmenspartnerschaften belief sich im Jahr 2023 auf insgesamt 0,38 Millionen US-Dollar.

• Partnerschaften mit Corporate Wellness-Programmen: 0,22 Millionen US-Dollar
• Kooperationen mit Versicherungsanbietern: 0,16 Millionen US-Dollar

Movano Inc. (MOVE) - Canvas Business Model: Value Propositions

The core value Movano Inc. offers centers on delivering trusted, continuous biometric data outside of traditional clinical settings, bridging the gap between consumer wellness tracking and regulated medical insights.

Medical-grade data from a comfortable, noninvasive ring form factor.

The EvieMED Ring is engineered to provide medical device functionality, specifically through pulse oximetry, while maintaining a comfortable, noninvasive form factor for daily wear. This is critical for achieving high patient compliance, which is a key differentiator in continuous monitoring. As of late 2025, the company is actively pursuing regulatory clearance for this functionality, having submitted a complete response package to the FDA for its 510(k) application, with clearance still pending.

Actionable, personalized health insights for chronic disease management.

Movano Inc. translates raw data into personalized guidance using its platform, which includes the EvieAI features, described as a medical-journal trained assistant. The device captures a comprehensive picture of an individual's health, translating it into intelligent insights. The platform tracks parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality, alongside logging mood and energy levels.

Remote patient monitoring tool for healthcare providers and payors.

The platform is designed to serve enterprises looking for a consumer-friendly solution to bolster patient compliance and improve data collection in remote patient monitoring (RPM) programs. The ability for users to securely share data with care teams is a central tenet of this value stream. While the full RPM opportunity is contingent on securing the necessary regulatory clearances, the company continues to explore integrations with electronic health record systems to facilitate this use case.

Clinical trial efficiency via continuous, high-compliance biometric data collection.

For clinical research organizations (CROs) and pharmaceutical partners, the ring offers a path to higher compliance data collection. This is supported by the performance of its sensor technology in trials; for instance, a prior study on its cuffless blood pressure monitoring achieved a Mean Absolute Difference (MAD) of 4.9 mmHg against a 7 mmHg threshold. Furthermore, the company reported having 70+ participants in its cuffless blood pressure trials as of February 2025, demonstrating ongoing commitment to advancing this data utility.

Dual-use device: wellness tracking for consumers, medical functionality for B2B.

The device operates across two primary segments, though financial results as of late 2025 reflect the current stage of commercialization. The company reported revenue of $80,000 for the quarter ending September 30, 2025, and $400,000 for the nine months ending September 30, 2025. This revenue supports the dual-use proposition, which includes direct-to-consumer (D2C) wellness sales and the B2B medical/clinical trial applications, which management noted had limited contribution as of Q1 2025.

Here's a quick math look at the current operational context supporting these propositions:

Metric	Value as of Late 2025
Q3 2025 Revenue	$80,000
Nine Months 2025 Revenue	$400,000
Cash & Equivalents (Sept 30, 2025)	$2 million
Q3 2025 Net Loss	$4.03 million
Total Assets (Sept 30, 2025)	$5.55 million
Market Capitalization (Approx. Nov 2025)	$7.68 million

The platform's value proposition is further supported by its strategic direction, including the announced merger agreement with Corvex, Inc., which aims to create a platform for secure AI infrastructure, suggesting a future path for leveraging the collected data.

The key features underpinning the value proposition include:

• Pulse oximetry for medical-grade SpO2 monitoring.
• Sleep, activity, mood, and energy level tracking.
• Wireless communication to a companion mobile application.
• Secure data sharing capabilities for care teams.
• EvieAI for personalized, intelligent insights.

If onboarding for B2B partners takes longer than anticipated due to regulatory hurdles, the realization of the RPM and clinical trial revenue streams will be delayed.

Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Customer Relationships

You're looking at how Movano Inc. (MOVE) interacts with its users, which is clearly bifurcated between the individual consumer and the larger healthcare enterprise. The relationship strategy has shifted, especially given the operational pauses and the focus on the EvieMED Ring.

Direct-to-consumer (D2C) sales model for the Evie Ring

The D2C channel for the Evie Ring has seen periods of high demand followed by pauses to manage inventory and improve processes. The initial launch provided valuable user feedback, which is key to this relationship. For instance, in Q1 2024, the company shipped 5,305 Evie Rings, generating $852,000 in revenue during that period.

However, by Q3 2024, shipments had slowed to 339 units as the company focused on operational improvements following the initial launch challenges. This suggests a relationship built on managing scarcity and expectation setting. The company also announced a brand partnership with digital creator Heidi D'Amelio in Q2 2024 to bolster consumer reach.

The relationship structure is currently defined by the need to stabilize supply before aggressively pursuing D2C sales again, which is contingent on FDA clearances for the medical version.

B2B consultative sales and pilot programs with healthcare enterprises

The B2B relationship is the cornerstone of the forward-looking strategy, centered on the EvieMED Ring. This is a consultative approach, not a simple transaction. Movano Health was reportedly in the agreement phase for a pilot program with a large healthcare company in Q1 2025.

Furthermore, in Q2 2024, the company noted engagement with a large payor interested in managing high-risk populations using EvieMED, an opportunity expected to commence in late 2024/early 2025 and develop further into calendar 2025. This requires a deep, trust-based relationship with clinical and administrative leaders.

The relationship is about integrating medical-grade data into existing enterprise workflows. This contrasts sharply with the individual consumer relationship.

Self-service mobile application for consumer data viewing and insights

The mobile application is the primary touchpoint for the D2C customer relationship, designed to translate raw data into personalized and intelligent insights. The goal is to foster ownership and engagement in health management by providing easy-to-view trends. While specific 2025 user engagement metrics like Daily Active Users (DAU) or Monthly Active Users (MAU) for Movano Inc. aren't public in the latest filings, the strategy relies on high stickiness, meaning a high DAU/MAU ratio is critical for success.

The relationship is maintained through:

• Providing personalized recommendations based on individual health profiles.
• Visualizations that make tracking progress simple.
• Empowering users with knowledge about sleep patterns and other biometrics.

Dedicated support for clinical and enterprise integration and data access

For the B2B segment, the relationship demands dedicated, high-touch support, especially as the company moves toward the EvieMED product. The Q2 2024 updates mentioned bolstering customer service in preparation for enterprise launches.

This support focuses on two main areas:

• Clinical integration of EvieMED data streams.
• Ensuring secure and compliant data access for enterprise partners.

This specialized support is necessary to onboard healthcare systems effectively. If onboarding takes 14+ days, churn risk rises, honestly.

Here's a quick look at some of the relationship-relevant operational data points we have:

Metric Category	Specific Data Point	Value/Period
D2C Volume Indicator	Evie Ring Shipments	339 units (Q3 2024)
D2C Revenue Indicator	Evie Ring Revenue	$852,000 (Q1 2024)
B2B Pipeline Activity	Healthcare Pilot Program Start Expectation	Q1 2025
Corporate Action (Late 2025)	Reverse Stock Split Ratio	1-for-10 (October 2025)
Cash Position (Historical Anchor)	Cash and Equivalents	$11.3 million (September 30, 2024)

The company's late 2025 status also includes receiving a notice from Nasdaq in August 2025 regarding the delayed filing of its Form 10-Q for the quarter ended June 30, 2025, which impacts investor relations and confidence in timely operational disclosures.

Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Channels

You're looking at how Movano Inc. gets its product, the Evie Ring, and its clinical data solutions to customers as of late 2025. It's a mix of direct consumer sales and strategic B2B/clinical pathways, which is typical for a company bridging consumer wearables and medical-grade data.

Direct e-commerce website for consumer sales of the Evie Ring.

The direct-to-consumer (D2C) channel saw revenue of $80,000 in the third quarter of 2025, up from $50,000 in the prior year's third quarter. For the first six months of 2025, total sales through channels were $0.309 million. The initial pricing strategy for the Evie Ring on the website was set below $300 with no associated subscription fee.

Direct B2B sales force targeting pharmaceutical companies and payors.

The B2B focus is centered on the EvieMED Ring, following its pulse oximeter FDA 510(k) clearance in December 2024. This clearance unlocked an estimated Total Addressable Market (TAM) of $40 billion in healthcare B2B opportunities. As of early 2025, Movano Inc. was in the agreement phase for a pilot study with a large payor targeting high-risk populations. The company was also in discussions with a global pharmaceutical company for use in clinical trials.

Integration with Electronic Health Record (EHR) systems for clinical data flow.

While specific Movano Inc. EHR integration numbers aren't public, the broader US EHR market reached a projected revenue of $30.1 billion in 2025. Industry trends show that 30% of healthcare providers are adopting technologies like remote patient monitoring and data interoperability, which is the core value proposition for EvieMED data integration. Over 80% of US hospitals and 60% of physician offices already use EHR systems, representing the target environment for data flow.

Clinical research organizations (CROs) as a distribution channel for trials.

Movano Inc. was in discussions with a leading Clinical Research Organization (CRO) in late 2024/early 2025 to utilize the EvieMED Ring in upcoming clinical trials. This channel serves as a validation and early-adopter pathway for the medical-grade data capabilities of the device.

Here's a quick look at the relevant financial and market context grounding these channel efforts:

Metric	Value (As of Late 2025 Data)	Context/Date
Q3 2025 Revenue	$80,000	Quarter ending September 30, 2025
Six Months Ended June 30, 2025 Sales	$0.309 million	First half of 2025
Q3 2025 Net Loss	$4.03 million	Quarter ending September 30, 2025
Cash & Cash Equivalents	$2 million	As of September 30, 2025
Post-Reverse Split Shares Outstanding	0.8 million	Effective October 10, 2025 (from 8.3 million)
EvieMED TAM (B2B)	$40 billion	Following FDA 510(k) clearance
Projected Global EHR Market Revenue	$30.1 billion	Forecast for 2025

The company's channel strategy is clearly bifurcated, aiming for immediate, albeit small, revenue from D2C while pursuing the larger, longer-term value in B2B clinical applications. The recent merger announcement with Corvex, Inc. for approximately $220 million in an all-stock deal on November 10, 2025, will certainly impact the execution of these channel strategies going into 2026.

Key channel activities and related data points include:

• Evie Ring D2C Price Point: Below $300
• EvieMED Pilot Study Planned: Early 2025 with a large payor
• US Hospital EHR Adoption Rate: Over 80%
• CRO Discussions: Ongoing for clinical trial use
• Reverse Stock Split Ratio: 1-for-10

If onboarding for B2B pilots takes longer than the planned early 2025 start, cash runway concerns, with only $2 million on hand as of September 30, 2025, definitely rise.

Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Customer Segments

You're looking at the customer base for Movano Inc. (MOVE) as of late 2025, right after their Q3 report. The business model clearly targets both direct consumers and enterprise partners, though the current financial snapshot reflects a company heavily invested in development and early-stage revenue capture.

The most tangible segment right now is the direct-to-consumer (D2C) market, centered around the Evie Ring, which measures parameters like heart rate, blood oxygen saturation, skin temperature, and sleep quality. For the third quarter of 2025, Movano Inc. reported total revenue of $0.08 million. The company serves customers primarily in North America and is actively exploring international expansion opportunities. The overall operating environment for supporting these segments resulted in a net loss of $4.03 million for Q3 2025.

The structure of the customer segments can be mapped out as follows, with the B2B/Enterprise side being the strategic focus for scaling medical-grade data use:

Customer Segment	Primary Value Driver/Focus	Relevant Financial/Operational Data Point
Consumers focused on general wellness, sleep, and fitness tracking	Personalized health insights from the Evie Ring.	Q3 2025 Revenue: $0.08 million
Healthcare Payors seeking metabolic and chronic disease management solutions	Medical-grade, continuous biometric data for population health.	Company reported a Q3 2025 net loss of $4.03 million, indicating high investment in platform development.
Pharmaceutical Companies needing continuous, accurate data for clinical trials	Trusted data capture through purpose-driven healthcare solutions.	Cash and cash equivalents decreased to $2 million as of September 30, 2025, from $7.9 million at the end of 2024.
Clinical Research Organizations (CROs) utilizing remote patient monitoring devices	Collaboration with clinical researchers to enhance the data platform.	Preliminary cash position as of March 31, 2025, was $4.3 million.
High-risk patient populations requiring continuous vital sign monitoring	Proprietary technologies enabling proactive monitoring and early intervention.	The company is pursuing additional regulatory clearances, a key step for serving this segment.

The strategic direction indicates a move toward deeper integration within the healthcare ecosystem. Movano Inc.'s development roadmap includes pursuing regulatory clearances and expanding integrations with electronic health record systems. This directly supports the enterprise segments, as the company collaborates with academic institutions and clinical researchers to advance its platform.

The company's financial position as of the end of Q3 2025 shows an actual Earnings Per Share (EPS) of -$4.73, which beat the consensus estimate of -$7.00 by $2.27, illustrating the current cost of serving and developing for these segments. The preliminary current ratio as of March 31, 2025, was 3.02, against accounts payable of $2.5 million.

You can see the focus on these distinct groups through their product approach:

• Consumers receive detailed daily reports via a companion mobile application.
• Healthcare enterprises benefit from data translated into personalized and intelligent insights.
• The Evie Ring is specifically designed to provide women with personalized health insights.
• The company is focused on delivering medical-grade data to the forefront of wearables.

Movano Inc. (MOVE) - Canvas Business Model: Cost Structure

You're looking at the expenses that drive the Movano Inc. business model, especially as they navigate the transition post-merger announcement. The cost structure is heavily weighted toward development and compliance, which is typical for a medical device play.

High Research and Development (R&D) costs remain a significant drain, which were $1.16 million in Q3 2025. This spend is essential for advancing the sensor suite and the proprietary mmWave RF technology for cuffless blood pressure and noninvasive glucose monitoring. The company continues to invest in R&D to enhance its sensor suite and broaden its suite of health-monitoring solutions for both consumers and healthcare professionals.

Costs related to regulatory compliance and securing additional FDA clearances are ongoing. The company achieved U.S. Food and Drug Administration (FDA) 510(k) clearance for the pulse oximeter in its EvieMED Ring in December 2024, which unlocked a Total Addressable Market (TAM) of $40 billion in healthcare B2B opportunities. Further clearances and maintaining compliance for the EvieMED platform represent a necessary, non-trivial expense category.

Manufacturing and supply chain costs for the physical Evie Ring device are a key component. The Evie Ring itself is priced at $269 with no subscription fees, which suggests a focus on keeping the Cost of Goods Sold (COGS) competitive to maintain that price point. Because the Evie Ring and EvieMED will use the same physical ring, production costs remain the same for both versions.

Selling, General, and Administrative (SG&A) expenses were reported at $1.22 million in Q3 2025. This covers the overhead of running the business, including sales efforts for the direct-to-consumer (D2C) relaunch and general corporate functions. For context, the net loss for Q3 2025 was $4.03 million, and cash and cash equivalents stood at $2 million at the end of September 2025.

Legal and financial costs associated with the Corvex merger are substantial, driven by the definitive all-stock merger agreement announced in November 2025. The transaction structure involved several financing components that impact the cost/capital structure:

• The merger valued Movano shares at $6.25 per share.
• The transaction valued Corvex at approximately $250.0 million and Movano at approximately $10.0 million.
• Corvex secured approximately $37.1 million in a private placement financing.
• Movano raised $3.0 million in a Series A preferred round.
• Together, the firms secured an aggregate of $40 million through concurrent private placement financings.
• Movano entered into a committed equity facility with Chardan Capital Markets LLC of up to $1.0 billion.
• A loan amendment extended maturity to March 31, 2026, adding a $3.0 million repayment premium upon asset sale before closing.

Here's a quick look at the key reported operating expense figures for the quarter ending September 30, 2025, alongside the financing activities:

Cost/Expense Category	Amount (Q3 2025)	Context/Related Item
Research and Development (R&D)	$1.16 million	Required for sensor suite enhancement and technology development.
Selling, General, and Administrative (SG&A)	$1.22 million	Covers overhead, sales, and general corporate operations.
Net Loss	$4.03 million	Overall profitability for the quarter.
Cash and Cash Equivalents	$2 million	Balance as of September 30, 2025.
Corvex Private Placement Financing	$37.1 million	Capital raised by Corvex concurrent with the merger.
Movano Series A Financing	$3.0 million	Equity capital raised by Movano concurrent with the merger.
Loan Repayment Premium	$3.0 million	Contingent cost related to the loan amendment tied to the merger.

The company anticipates the need for further financing to support its operations beyond the first quarter of 2026. Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Revenue Streams

You're looking at the hard numbers for Movano Inc.'s revenue generation as of late 2025. Honestly, the story here is one of transition-moving from initial product sales to building out the more structured, high-value B2B/clinical revenue channels. The current figures reflect that early commercial stage.

The primary recognized revenue stream centers on the Sales of the Evie Ring to the direct-to-consumer market. This is the initial path to market for the consumer-facing wearable, leveraging digital marketing to reach women directly through the company's website. However, the company is clearly positioning for a pivot toward more institutional revenue.

The other key components of the intended revenue mix involve the EvieMED Ring and partnerships. This includes potential B2B licensing or subscription fees for the EvieMED Ring and data platform, which is the FDA-cleared version of the device. Also critical is capturing Pilot study and clinical trial revenue from pharmaceutical and payor partners, which validates the medical utility and provides non-product revenue while the EvieMED is being adopted.

Here's a quick look at the top-line financial performance as reported:

Revenue Metric	Amount
Revenue for the nine months ended September 30, 2025	$0.389 million
Revenue for the quarter ended September 30, 2025	$0.08 million
Revenue in Fiscal Year 2024	$1.01 million
Trailing Twelve Months (TTM) revenue as of December 2025	$0.47 million

The difference between the nine-month figure and the TTM figure suggests the revenue recognized in the final quarter of 2025 (October through December) was relatively small, or the TTM calculation is based on a slightly different period ending in December 2025, which is common in reporting cycles. What this estimate hides is the exact mix of DTC versus any early B2B revenue recognized by year-end.

The overall revenue generation strategy is built on these distinct pillars:

• Direct sales of the consumer Evie Ring via DTC channels.
• Future recurring revenue from B2B subscriptions for the EvieMED platform.
• Project-based revenue from clinical trials with partners.
• Revenue from payor partnerships utilizing the device data.

To be fair, the current revenue base is small, reflecting the focus on regulatory milestones and building inventory for larger B2B contracts. Finance: draft 13-week cash view by Friday.